Читать книгу Veterinary Surgical Oncology - Группа авторов - Страница 47

These therapies include gene therapy (e.g. viral and non‐viral vectors); targeting signal transduction that regulates cell growth, differentiation, survival, and death (e.g. via inhibition of protein kinase); anti‐angiogenic factors (including metronomic chemotherapy and cyclo‐oxygenase‐2 inhibitors); agents that can inhibit DNA methyltransferase‐1 function; histone deacetylases; proteasome inhibitors; heat shock protein 90 inhibitors; Poly adenosine diphosphate (ADP)‐ribose polymerase (PARP) inhibitors; and carbonic anhydrase IX inhibitors (Argyle et al. 2013).

A thinking surgical oncologist is always aware of the animal as a whole and how the behavior of the specific cancer in the specific patient influences the surgeon’s role. The surgeon is cognizant of paraneoplastic syndromes, appropriate imaging and staging prior to and during surgery, appropriate support and follow‐up care, and how various modalities can be used synergistically to achieve the maximal outcome with minimal morbidity. Tables 2.1–2.3 outline various treatment modalities and published outcomes of these treatments for various types of cancers in dogs and cats.